ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Earnings for ESSA Pharma Inc. (EPIX)
Earnings in 2023 (TTM): $-26,580,743
According to ESSA Pharma Inc.'s latest financial reports the company's current earnings (TTM) are $-26,580,743. The earnings displayed on this page is the company's Pretax Income.
Earnings history of ESSA Pharma Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-26,580,743 | $-26,582,343 |
| 2022 | $-35,215,000 | $-35,103,000 |
| 2021 | $-36,839,810 | $-36,805,461 |
| 2020 | $-23,734,000 | $-23,445,000 |
| 2019 | $-10,403,000 | $-10,441,000 |
| 2018 | $-11,603,000 | $-11,630,000 |
| 2017 | $-4,383,000 | $-4,499,000 |
| 2016 | $-12,989,000 | $-13,140,000 |
| 2015 | $-8,568,167 | $-8,568,167 |
| 2014 | $-1,823,929 | $-1,823,929 |
| 2013 | $-1,371,321 | $-1,371,321 |
| 2012 | $-1,938 | $-1,938 |